• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

循环无细胞 DNA 中激活型 EGFR 突变的数量是监测奥希替尼反应的标志物。

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.

机构信息

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Medical Oncology Unit, University Hospital of Parma, Parma, Italy.

出版信息

Br J Cancer. 2018 Nov;119(10):1252-1258. doi: 10.1038/s41416-018-0238-z. Epub 2018 Nov 6.

DOI:10.1038/s41416-018-0238-z
PMID:30397287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6251035/
Abstract

BACKGROUND

Circulating cell-free DNA (cfDNA) may help understand the molecular response to pharmacologic treatment and provide information on dynamics of clonal heterogeneity. Therefore, this study evaluated the correlation between treatment outcome and activating EGFR mutations (act-EGFR) and T790M in cfDNA in patients with advanced NSCLC given osimertinib.

METHODS

Thirty-four NSCLC patients resistant to first/second-generation EGFR-TKIs, positive for both act-EGFR and T790M in cfDNA at the time of progression were enrolled in this study. Plasma samples were obtained at osimertinib baseline and after 3 months of therapy; cfDNA was analyzed by droplet digital PCR and results were expressed as mutant allele frequency (MAF).

RESULTS

At baseline, act-EGFR MAF was significantly higher than T790M (p < 0.0001). act-EGFR MAF and T790M/act-EGFR MAF ratio were significantly correlated with disease response (p = 0.02). Cut-off values of act-EGFR MAF and T790M/act-EGFR ratio of 2.6% and 0.22 were found, respectively. The PFS of patients with act-EGFR MAF of > 2.6% and < 2.6%, were 10 months vs. not reached, respectively (p = 0.03), whereas patients with T790M/act-EGFR ≤ 0.22 had poorer PFS than patients with a value of > 0.22 (6 months vs. not reached, respectively, p = 0.01).

CONCLUSION

act-EGFR MAF and T790M/act-EGFR MAF ratio are potential markers of outcome in patients treated with osimertinib.

摘要

背景

循环游离 DNA（cfDNA）可帮助了解药物治疗的分子反应，并提供有关克隆异质性动态的信息。因此，本研究评估了奥希替尼治疗的晚期 NSCLC 患者中 cfDNA 中治疗反应与激活的 EGFR 突变（act-EGFR）和 T790M 之间的相关性。

方法

本研究纳入了 34 名对第一代/第二代 EGFR-TKI 耐药、进展时 cfDNA 中同时存在 act-EGFR 和 T790M 的 NSCLC 患者。在奥希替尼基线和治疗 3 个月时采集血浆样本；通过液滴数字 PCR 分析 cfDNA，并以突变等位基因频率（MAF）表示结果。

结果

基线时，act-EGFR MAF 明显高于 T790M（p<0.0001）。act-EGFR MAF 和 T790M/act-EGFR MAF 比值与疾病反应显著相关（p=0.02）。分别发现 act-EGFR MAF 和 T790M/act-EGFR MAF 比值的截断值为 2.6%和 0.22。act-EGFR MAF>2.6%和<2.6%的患者的 PFS 分别为 10 个月和未达到，分别（p=0.03），而 T790M/act-EGFR≤0.22 的患者的 PFS 比 T790M/act-EGFR>0.22 的患者差（6 个月与未达到，分别，p=0.01）。

结论

act-EGFR MAF 和 T790M/act-EGFR MAF 比值是奥希替尼治疗患者结局的潜在标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/be3219d70a34/41416_2018_238_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/8ea44ed0718b/41416_2018_238_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/5ad5acfdcccf/41416_2018_238_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/8104e25ab4d1/41416_2018_238_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/ed0143a5544e/41416_2018_238_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/be3219d70a34/41416_2018_238_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/8ea44ed0718b/41416_2018_238_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/5ad5acfdcccf/41416_2018_238_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/8104e25ab4d1/41416_2018_238_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/ed0143a5544e/41416_2018_238_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c036/6251035/be3219d70a34/41416_2018_238_Fig5_HTML.jpg

相似文献

1
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.循环无细胞 DNA 中激活型 EGFR 突变的数量是监测奥希替尼反应的标志物。
Br J Cancer. 2018 Nov;119(10):1252-1258. doi: 10.1038/s41416-018-0238-z. Epub 2018 Nov 6.
2
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.血浆 EGFR T790M 突变筛查和奥希替尼在血浆 T790M 阳性非小细胞肺癌中的疗效的 2 期研究：西日本肿瘤学组 8815L/LPS 研究。
Cancer. 2020 Jan 1;126(9):1940-1948. doi: 10.1002/cncr.32749. Epub 2020 Feb 5.
3
Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.奥希替尼用于 EGFR T790M 突变阳性、体能状况较差的非小细胞肺癌患者。
Jpn J Clin Oncol. 2019 Jul 1;49(7):671-675. doi: 10.1093/jjco/hyz041.
4
Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).通过检测 EGFR T790M 阳性非小细胞肺癌患者循环肿瘤 DNA 中的 EGFR 突变等位基因丰度预测奥希替尼治疗效果（WJOG8815L）。
Mol Oncol. 2021 Jan;15(1):126-137. doi: 10.1002/1878-0261.12841. Epub 2020 Nov 17.
5
Lessons learned from routine, targeted assessment of liquid biopsies for T790M resistance mutation in patients with mutant lung cancers.从常规的液体活检中检测 T790M 耐药突变用于治疗突变型肺癌患者的经验教训。
Acta Oncol. 2019 Nov;58(11):1634-1639. doi: 10.1080/0284186X.2019.1645354. Epub 2019 Jul 26.
6
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib.表皮生长因子受体突变的等位基因频率可预测奥希替尼治疗的晚期 EGFR T790M 阳性非小细胞肺癌患者的生存情况。
Target Oncol. 2021 Jan;16(1):77-84. doi: 10.1007/s11523-020-00781-3. Epub 2020 Dec 3.
7
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.从初始治疗到出现耐药：奥希替尼治疗 T790M 阳性晚期 NSCLC 患者的血浆监测及耐药机制研究。
Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19.
8
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.在一名接受奥希替尼治疗后病情进展的表皮生长因子受体（EGFR）（L858R/T790M）非小细胞肺癌（NSCLC）患者中，出现了新的、占主导地位的获得性EGFR溶剂前沿突变，位于甘氨酸796（G796S/R），同时伴有C797S/R和亮氨酸792（L792F/H）突变。
Lung Cancer. 2017 Jun;108:228-231. doi: 10.1016/j.lungcan.2017.04.003. Epub 2017 Apr 12.
9
Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.既往接受 EGFR-TKIs 治疗对携带 EGFR T790M 突变的非小细胞肺癌患者奥希替尼疗效的影响。
Thorac Cancer. 2021 Feb;12(3):329-338. doi: 10.1111/1759-7714.13742. Epub 2020 Nov 21.
10
Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.应用数字液滴 PCR 对日本非小细胞肺癌患者进行连续的游离细胞 DNA 评估，监测表皮生长因子受体 C797S 突变。
Cancer Sci. 2021 Jun;112(6):2371-2380. doi: 10.1111/cas.14879. Epub 2021 May 2.

引用本文的文献

1
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.异柠檬酸脱氢酶 1 突变可在血浆无细胞 DNA 中检测到，并与胶质瘤患者的生存结局相关。
BMC Cancer. 2024 Jan 3;24(1):31. doi: 10.1186/s12885-023-11726-0.
2
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.奥希替尼治疗 T790M 阳性 EGFR 突变型 NSCLC 患者中循环肿瘤 DNA 的预测意义。
Sci Rep. 2023 Nov 27;13(1):20848. doi: 10.1038/s41598-023-48210-5.
3
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications.

本文引用的文献

1
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.奥希替尼治疗原发性耐药导致小细胞肺癌转化：液体再活检T790M 检测问题。
Lung Cancer. 2018 Jan;115:21-27. doi: 10.1016/j.lungcan.2017.11.011. Epub 2017 Nov 13.
2
Patients with NSCLC may display a low ratio of p.T790M activating EGFR mutations in plasma at disease progression: implications for personalised treatment.非小细胞肺癌患者在疾病进展时，血浆中激活表皮生长因子受体（EGFR）的p.T790M突变比例可能较低：对个性化治疗的启示。
Oncotarget. 2017 Sep 15;8(49):86056-86065. doi: 10.18632/oncotarget.20947. eCollection 2017 Oct 17.
3
非小细胞肺癌的液体活检：具有多种临床意义的探索。
Int J Mol Sci. 2023 Jun 28;24(13):10803. doi: 10.3390/ijms241310803.
4
Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.ctDNA 早期动力学联合 cfDNA 和血清 CEA 对晚期非小细胞肺癌 EGFR-TKI 治疗的预测价值。
Thorac Cancer. 2022 Nov;13(22):3162-3173. doi: 10.1111/1759-7714.14668. Epub 2022 Oct 4.
5
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?液体活检与非小细胞肺癌：我们是否初见端倪？
Br J Cancer. 2022 Aug;127(3):383-393. doi: 10.1038/s41416-022-01777-8. Epub 2022 Mar 9.
6
The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.晚期非小细胞肺癌中表皮生长因子受体（EGFR）T790M突变丰度与奥希替尼疗效的相关性
Transl Cancer Res. 2021 Jun;10(6):2895-2905. doi: 10.21037/tcr-21-223.
7
EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.通过循环肿瘤DNA（ctDNA）二代测序（NGS）分析确定的对奥希替尼耐药的表皮生长因子受体（EGFR）依赖性机制可识别出预后较好的患者。
Transl Lung Cancer Res. 2021 Nov;10(11):4084-4094. doi: 10.21037/tlcr-21-679.
8
Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review.液滴数字PCR在肿瘤学中的当前及新兴应用：最新综述
Mol Diagn Ther. 2022 Jan;26(1):61-87. doi: 10.1007/s40291-021-00562-2. Epub 2021 Nov 13.
9
A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.奥希替尼治疗获得性 EGFR-T790M 突变的晚期非小细胞肺癌患者的综合预后分析：一项真实世界研究。
J Cancer Res Clin Oncol. 2022 Sep;148(9):2475-2486. doi: 10.1007/s00432-021-03797-y. Epub 2021 Sep 18.
10
Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions.COBAS表皮生长因子受体半定量指数（SQI）用于EGFR外显子19缺失的非小细胞肺癌患者血浆循环游离DNA检测的技术评估
Diagnostics (Basel). 2021 Jul 22;11(8):1319. doi: 10.3390/diagnostics11081319.
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
4
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.连续液体活检揭示了EGFR驱动基因突变的动态变化，并表明EGFR扩增是NSCLC中对奥希替尼耐药的一种新机制。
Lung Cancer. 2017 Jun;108:238-241. doi: 10.1016/j.lungcan.2017.04.004. Epub 2017 Apr 10.
5
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.在一名接受奥希替尼治疗后病情进展的表皮生长因子受体（EGFR）（L858R/T790M）非小细胞肺癌（NSCLC）患者中，出现了新的、占主导地位的获得性EGFR溶剂前沿突变，位于甘氨酸796（G796S/R），同时伴有C797S/R和亮氨酸792（L792F/H）突变。
Lung Cancer. 2017 Jun;108:228-231. doi: 10.1016/j.lungcan.2017.04.003. Epub 2017 Apr 12.
6
Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.奥希替尼获得性耐药后吉非替尼成功治疗晚期非小细胞肺癌
J Thorac Oncol. 2017 Jun;12(6):e78-e80. doi: 10.1016/j.jtho.2017.02.014.
7
The feasibility of using mutation detection in ctDNA to assess tumor dynamics.利用循环肿瘤DNA中的突变检测来评估肿瘤动态变化的可行性。
Int J Cancer. 2017 Jun 15;140(12):2642-2647. doi: 10.1002/ijc.30620. Epub 2017 Mar 2.
8
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.奥希替尼对检测到 T790M 突变的 EGFR 突变型 NSCLC 患者的疗效：基于循环肿瘤 DNA 的研究。
Ann Oncol. 2017 Apr 1;28(4):784-790. doi: 10.1093/annonc/mdx017.
9
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.奥希替尼或铂类培美曲塞用于治疗表皮生长因子受体T790M阳性肺癌
N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
10
High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.在一名奥希替尼进展后对克唑替尼治疗有症状反应的患者中，高MET扩增水平作为对奥希替尼（AZD9291）的耐药机制。
Lung Cancer. 2016 Aug;98:59-61. doi: 10.1016/j.lungcan.2016.05.015. Epub 2016 May 25.